Leukemia Research
Volume 30, Issue 9 , Pages 1113-1118 , September 2006

Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia

  • Geothy Kochethu

      Affiliations

    • Department of Haematology, Heart of England NHS Trust, Bordesley Green East, Birmingham, UK
    • ,
  • Julio Delgado

      Affiliations

    • Department of Haematology, Heart of England NHS Trust, Bordesley Green East, Birmingham, UK
    • ,
  • Chris Pepper

      Affiliations

    • Department of Haematology, Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
    • ,
  • Jane Starczynski

      Affiliations

    • Department of Haematology, Heart of England NHS Trust, Bordesley Green East, Birmingham, UK
    • ,
  • Laura Hooper

      Affiliations

    • Department of Haematology, Heart of England NHS Trust, Bordesley Green East, Birmingham, UK
    • ,
  • Satish Krishnan

      Affiliations

    • Department of Haematology, Heart of England NHS Trust, Bordesley Green East, Birmingham, UK
    • ,
  • Christopher Fegan

      Affiliations

    • Department of Haematology, Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
    • ,
  • Guy Pratt

      Affiliations

    • Department of Haematology, Heart of England NHS Trust, Bordesley Green East, Birmingham, UK
    • Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 121 4243698; fax: +44 121 7667530.

Received 17 October 2005 ,Revised 23 December 2005 ,Accepted 27 December 2005.

References 

  1. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000;4(1):5–21
  2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310
  3. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol. 2001;3(12):E277–E286
  4. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 1996;47:285–301
  5. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916
  6. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7(2):961–963
  7. Sjalander A, Birgander R, Kivela A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 1995;45(3):144–149
  8. Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002;21(1):9–21
  9. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–365
  10. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23(19):3328–3337
  11. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196–199
  12. Biros E, Kalina I, Biros I, Kohut A, Bogyiova E, Salagovic J, et al. Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma. 2001;48(5):407–411
  13. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206
  14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215
  15. Biros E, Kalina I, Kohut A, Stubna J, Salagovic J. Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer. 2001;31(2–3):157–162
  16. Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Hoy T, et al. The P2X7 receptor gene polymorphism 1513 A→C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003;123:66–71
  17. Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D, et al. Common polymorphism G(−248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukema once treatment is initiated. J Clin Oncol. 2005;23(7):1514–1521
  18. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3(4):387–402
  19. Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25(1):47–54
  20. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092–1100

PII: S0145-2126(06)00010-5

doi: 10.1016/j.leukres.2005.12.014

Leukemia Research
Volume 30, Issue 9 , Pages 1113-1118 , September 2006

Article Tools

* Image Usage & Resolution